Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 18;12(6):1027-1036.
doi: 10.18240/ijo.2019.06.24. eCollection 2019.

The efficacy and safety of besifloxacin for acute bacterial conjunctivitis: a Meta-analysis

Jun-Jie Wang  1 , Xin-Yi Gao  2 , Hong-Zhuo Li  3 , Shan-Shuang Du  2
Affiliations

The efficacy and safety of besifloxacin for acute bacterial conjunctivitis: a Meta-analysis

Jun-Jie Wang et al. Int J Ophthalmol. .

Retraction in

  • Retraction Notice.
    [No authors listed] [No authors listed] Int J Ophthalmol. 2019 Sep 18;12(9):1401. eCollection 2019. Int J Ophthalmol. 2019. PMID: 31544033 Free PMC article.

Abstract

Aim: To evaluate the relative efficacy and safety of besifloxacin for treatment of acute bacterial conjunctivitis.

Methods: A comprehensive search in PubMed, EMBASE Web of Science, Cochrane Central Database and CNKI was undertaken for randomized controlled trials (RCTs) comparing besifloxacin with other treatments or placebo. The primary outcome measures were clinical resolution, rates of bacterial eradication, individual clinical outcomes, cure rates, and bacterial eradication rates of different kinds of pathogens. Safety outcomes were the number of adverse effects (AEs). The final search was performed on August 2018.

Results: Eight RCTs were included. Five studies compared the efficacy and safety of besifloxacin with placebo, 2 studies compared besifloxacin with moxifloxacin, and 1 study compared besifloxacin with gatifloxacin. A total of 3105 patients met the inclusion criteria. Besifloxacin presented higher efficacy and safety than did placebo in clinical resolution, rates of bacterial eradication, individual clinical outcomes, cure rates, bacterial eradication rates of different kinds of pathogens and the number of AEs. There was no significant difference between besifloxacin and moxifloxacin or gatifloxacin in the comparison items mentioned above.

Conclusion: Besifloxacin is highly effective and safe for treatment of acute bacterial conjunctivitis. Further comparative trials regarding the effect of besifloxacin for treatment of acute bacterial conjunctivitis will aid in treatment decisions.

Keywords: Meta-analysis; acute bacterial conjunctivitis; besifloxacin; randomized controlled trials.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow diagram of studies included in this Meta-analysis.
Figure 2
Figure 2. Risk of bias of included studies.
Figure 3
Figure 3. Estimated odds ratio for changes in clinical resolution at day 4.
Figure 4
Figure 4. Estimated odds ratio for changes in clinical resolution at day 8.
Figure 5
Figure 5. Estimated odds ratio for changes in bacterial eradication rates at day 4.
Figure 6
Figure 6. Estimated odds ratio for changes in bacterial eradication rates at day 8.
Figure 7
Figure 7. Estimated odds ratio for changes in ocular discharge and bulbar conjunctival injection
A: Resolution of ocular discharge at day 4; B: Resolution of ocular discharge at day 8; C: Normal bulbar conjunctival injection at day 4; D: Normal bulbar conjunctival injection at day 8.
Figure 8
Figure 8. Estimated odds ratio for changes in cure rates at day 4.
Figure 9
Figure 9. Estimated odds ratio for changes in cure rates at day 8.
Figure 10
Figure 10. Estimated odds ratio for the risk of AEs.
Figure 11
Figure 11. Sensitivity analysis for the bacterial eradication rates of Gram-positive bacteria at day 4.
Figure 12
Figure 12. Sensitivity analysis for AEs.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sheikh A, Hurwitz B, van Schayck CP, McLean S, Nurmatov U. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2012;(9):CD001211. - PubMed
    1. Alfonso SA, Fawley JD, Alexa Lu X. Conjunctivitis. Prim Care. 2015;42(3):325–345. - PubMed
    1. Haas W, Gearinger LS, Usner DW, Decory HH, Morris TW. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. Clin Ophthalmol. 2011;5:1369–1379. - PMC - PubMed
    1. Chikviladze D, Nikuradze N, Gachechiladze Kh, Miqeladze M, Metreveli D. Microbial structure of acute bacterial conjunctivitis. Georgian Med News. 2013;(216):12–15. - PubMed
    1. Høvding G. Acute bacterial conjunctivitis. Acta Ophthalmol. 2008;86(1):5–17. - PubMed

Publication types

LinkOut - more resources